



Two Cases of Atopic Dermatitis that Healed Completely after Several Intradermal Injections with Non-Specific Antigen Preparation

Kimihiko Okazaki*

Abstract

Mutual exchanges between specific and non-specific antibody molecules on receptors on the surface of mast cells should take place after an accumulation of non-specific antibodies in the patients' bodies. These exchanges will bring about decompositions of combinations of mast cells and specific antibodies. These decompositions equal eliminations of causes of allergic diseases.

Keywords

Equilibrium; Mutual exchange of antibody molecules; Specificity; Non-specificity

Introduction

According to the traditional concept of the contemporary Immunology, neither autoimmune diseases nor allergic diseases can be cured completely. Nevertheless, a fortunate coincidence led the author to discover a novel concept that eliminations of the causes of these diseases are possible. In other words, combinations of pathogenic antibodies with responsible cells, namely, cytolytic T lymphocytes in cases of autoimmune diseases and mast cells in cases of allergic diseases, can be decomposed by replacing the pathogenic antibodies with non-specific antibodies. In more detail, intradermal injections with a non-specific antigen preparation induce productions of non-specific antibodies in the body of the patient. Repetitions of the injections bring about an accumulation of them. Accumulated non-specific antibodies will occupy most of the receptors on the surface of responsible cells. When the accumulation reaches the sufficient level, virtually no pathogenic antibodies would remain on the receptors. That is, no causes of the diseases remain.

It is well established that the etiology of allergic diseases is that combinations of mast cells and allergen-specific antibodies cause allergic symptoms when the patients meet allergens. Similarly, the etiology of auto-immune diseases is that combinations of cytolytic T lymphocytes and organ-specific antibodies cause injury of the organ. A most plain idea would be that break down of the above-mentioned combinations must bring about disappearance of causes of the diseases.

*Corresponding author: Kimihiko Okazaki, Okazaki Medical Clinic, Ukyoku, Kyoto, Japan, E-mail: ma13081x@ma1.seikyoku.ne.jp

Received: December 14, 2017 Accepted: January 11, 2018 Published: January 16, 2018

To work out the above mentioned concept, it is necessary to have the patients make non-specific antibodies for themselves. In order for the patients to do so, they need to receive intradermal injections with non-specific antigen preparations. Consequently, non-specific antibodies accumulate in the patients' bodies, which may replace specific antibodies from respective cells bringing about elimination of causes of the diseases. Needless to mention, where there is no cause, there is no disease. Details are demonstrated elsewhere [1]. The conceptual basis of antibodies' mutual exchange is existence of equilibrium state among antibody molecules in the vicinity of receptors, which was first proposed by Porter [2]. One of the contemporary trends concerning treatments of allergic diseases is an intravenous infusion of solution of non-specific antibody preparation. However, a large number of these infusions are dangerous because anti-antibody antibody might be produced in the recipient's body, which may cause an anaphylactic reaction.

Case 1

An 18-year-old woman (A.N.) visited the author's clinic on January 14, 2016. She said that she had been suffering from an atopic dermatitis for approximately 2 years. She received intradermal injections at her navel-edge with 0.1ml of 100,000,000-fold with saline diluted Neurotropin; a product of Nippon Pharmaceutical Company(Osaka), consisting of an extract of rabbit skin inflamed by inoculation of Vaccinia virus, totally 5 times at 1~2 week intervals. She became free of atopic dermatitis thereafter.

Case 2

A 67-year-old woman (K.M.) visited the author's clinic on October 19, 2017. She said that she had been suffering from an atopic dermatitis since her childhood. She received intradermal injections at her navel-edge with 0.1ml of 10,000,000-fold with saline diluted Neurotropin 6 times at 2~3 day intervals. She also received intradermal injections with 0.1ml of 100,000,000-fold diluted Neurotropin 3 times at her navel-edge at 4~5 day intervals. She also received intradermal injections with 0.1ml of 10 to the 14-fold diluted Neurotropin at her navel-edge 5 times at 2~5 day intervals. She became free of atopic dermatitis thereafter. The reason why the extent of dilution of Neurotropin was raised is because the action of the injection would have been negative otherwise. In more detail, as accumulation of non-specific antibody proceeds, the patient's synthetic capacity of non-specific antibodies decreases. Consequently, excessively injected non-specific antigen would attract some of the previously produced non-specific antibodies, which are attached to receptors. The attraction mentioned above comes from the affinity between antigen and its specific antibody. The same is true between non-specific antigen and its antibody.

Discussion

Elimination of cause of immunological disease may appear inconceivable. Fortunately, it is practically accomplished safely and definitely owing to the novel concept.

Conclusion

The concept that is demonstrated here might be a breakthrough to a new world where no incurable diseases exist.

References

1. Okazaki K, (2009) Therapeutic Significance of Non-Specific Antigens as Anti-Allergic and Anti- Autoimmune Agents. Pharmacometrics 76: 105-107.
2. Porter RR (1959) The hydrolysis of rabbit gamma-globulin and antibodies by crystalline papain. Biochem J 73: 119.

Author Affiliations

[Top](#)

Okazaki Medical Clinic, Ukyoku, Kyoto, Japan

Submit your next manuscript and get advantages of SciTechnol submissions

- ❖ 80 Journals
- ❖ 21 Day rapid review process
- ❖ 3000 Editorial team
- ❖ 5 Million readers
- ❖ More than 5000 
- ❖ Quality and quick review processing through Editorial Manager System

Submit your next manuscript at • www.scitechnol.com/submission